drugset / Trial / NCT00226330
GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
Timeline
- Start
- 2005-03
- Primary completion
- 2006-12
- Completion
- 2006-12
Outcome
Outcome not reported
Stopped: “The development program has been terminated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pioglitazone | Small molecule | 15 mg | — |
| Subject | Pioglitazone | Small molecule | 30 mg | — |
| Subject | Pioglitazone | Small molecule | 45 mg | — |
| Subject | Tesaglitazar | Small molecule | 0.5 mg | Oral |
| Subject | Tesaglitazar | Small molecule | 1 mg | Oral |